MTORC1 Inhibition Is an Effective Treatment for Sporadic Renal Angiomyolipoma.

ABSTRACT:

Introduction

Renal angiomyolipoma (AML) is the most common benign renal tumor. Despite a generally benign histology, AML can result in significant morbidity, from intra-abdominal hemorrhage and reduction in kidney function. While classically associated with the autosomal dominant disorder tuberous sclerosis complex (TSC) or with pulmonary lymphangioleiomyomatosis, most AMLs are sporadic. Mammalian target of rapamycin complex 1 (mTORC1) inhibitors (e.g., sirolimus) have been found to be effective in treating TSC- or lymphangioleiomyomatosis-associated AML, but to date it is unknown whether this strategy is effective for sporadic AML.

Methods

We stained tumor specimens of sporadic AML patients for pS6 to assess for mTORC1 activation.

Results

We detected strong activatio

SUBMITTER: Pleniceanu O 

PROVIDER: S-EPMC5762943 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature